Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
NCT00202930Phase 2Terminated
- Start
- Jul 2005
- Primary completion
- Dec 2008
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Opsoclonus myoclonus syndrome (OMS). Primary endpoints: Feasibility of Using 4 Weekly Rituximab Infusions at 4 weeks and Toxicity of Rituximab at 270 days. Started Jul 2005; status: terminated.
02
Drugs
rituximab
03
Conditions
Opsoclonus myoclonus syndrome (OMS)
Beyond the preview
Go deeper on NCT00202930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202930.